Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J
Jerusalem Mental Health Center, Kfar Shaul Hospital, Israel.
Acta Psychiatr Scand. 2000 Dec;102(6):461-5. doi: 10.1034/j.1600-0447.2000.102006461.x.
This paper reports the results of risperidone treatment in seven patients (six adults and one adolescent) diagnosed as suffering from Prader-Willi syndrome (PWS) accompanied by severe behavioural disturbances. Risperidone was chosen following the failure of these patients to respond to other acknowledged modes of treatment for the psychiatric manifestations of PWS.
This was a prospective open-label study. Measures of Clinical Global Impression Scale (CGIS), Retrospective Overt Aggression Scale (ROAS), Aggression Score (AS) and weight were obtained during two baseline visits and again following 37 weeks of treatment with risperidone.
Low dosages (1-3 mg/day; 1.6 mg/day on average) of risperidone brought about notable clinical improvement with no apparent adverse side effects. All measures evaluated--general behaviour, CGIS, OAS and weight--reacted favourably to the treatment protocol.
The preliminary results presented here suggest that risperidone is useful in treating PWS due to its positive effect on the disruptive behavioural symptoms that accompany it.
本文报告了利培酮治疗7例被诊断为患有普拉德-威利综合征（PWS）并伴有严重行为障碍的患者（6名成人和1名青少年）的结果。在这些患者对PWS精神症状的其他公认治疗方式无反应后，选择了利培酮。
这是一项前瞻性开放标签研究。在两次基线访视期间以及利培酮治疗37周后，获取临床总体印象量表（CGIS）、回顾性明显攻击量表（ROAS）、攻击评分（AS）和体重的测量值。
低剂量（1 - 3毫克/天；平均1.6毫克/天）的利培酮带来了显著的临床改善，且无明显不良副作用。所有评估指标——一般行为、CGIS、OAS和体重——对治疗方案均有良好反应。
此处呈现的初步结果表明，利培酮因其对伴随的破坏性行为症状有积极作用，对治疗PWS有用。
